Department of Human Parasitology; Shandong University School of Medicine; Shandong, P.R. China.
Hum Vaccin Immunother. 2013 Dec;9(12):2566-77. doi: 10.4161/hv.26088. Epub 2013 Aug 16.
Vaccination is a proven strategy for protection from disease. An ideal vaccine would include antigens that elicit a safe and effective protective immune response. HLA-restricted epitope vaccines, which include T-lymphocyte epitopes restricted by HLA alleles, represent a new and promising immunization approach. In recent years, research in HLA-restricted epitope vaccines for the treatment of tumors and for the prevention of viral, bacterial, and parasite-induced infectious diseases have achieved substantial progress. Approaches for the improvement of the immunogenicity of epitope vaccines include (1) improving the accuracy of the methods used for the prediction of epitopes, (2) making use of additional HLA-restricted CD8(+) T-cell epitopes, (3) the inclusion of specific CD4(+) T-cell epitopes, (4) adding B-cell epitopes to the vaccine construction, (5) finding more effective adjuvants and delivery systems, (6) using immunogenic carrier proteins, and (7) using multiple proteins as epitopes sources. In this manuscript, we review recent research into HLA-restricted epitope vaccines.
疫苗接种是预防疾病的有效策略。理想的疫苗应包含能引发安全有效免疫应答的抗原。HLA 限制性表位疫苗包括受 HLA 等位基因限制的 T 淋巴细胞表位，代表了一种新的、有前途的免疫接种方法。近年来，针对肿瘤治疗和预防病毒、细菌和寄生虫感染性疾病的 HLA 限制性表位疫苗的研究取得了实质性进展。提高表位疫苗免疫原性的方法包括：（1）提高预测表位方法的准确性；（2）利用额外的 HLA 限制性 CD8+T 细胞表位；（3）包含特定的 CD4+T 细胞表位；（4）在疫苗构建中添加 B 细胞表位；（5）寻找更有效的佐剂和传递系统；（6）使用免疫原性载体蛋白；（7）使用多种蛋白质作为表位来源。在本文中，我们综述了 HLA 限制性表位疫苗的最新研究进展。
